Why the study?
Despite aggressive LDL-C lowering recommendations, accumulating evidence associates low LDL-C with increased bleeding risk in patients receiving antithrombotic therapy through mechanisms that remain incompletely understood.
Does aggressive LDL-C lowering increase bleeding risk in patients on antithrombotic therapy?
Does aggressive LDL-C lowering increase bleeding risk in patients on antithrombotic therapy?
Aggressive LDL-C lowering may increase bleeding risk in patients receiving antithrombotic therapy, highlighting the need to carefully balance ischemic benefits with bleeding risks.
Answers are grounded in this paper and cite their sources.
May warrant caution with aggressive LDL-C lowering on antithrombotics; leaves open causality and optimal targets for RCTs.
The clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. Although the cardiovascular and all-cause mortality benefit of PCSK9i remains inconclusive, current cholesterol management guidelines have been modified toward more aggressive goals for lowering low-density lipoprotein cholesterol (LDL-C). Consequently, the emerging concept of "the lower the better" has become the paradigm of ASCVD prevention. However, there is evidence from observational studies of a U-shaped association between baseline LDL-C levels and all-cause mortality in population-based cohorts. Among East Asian populations, low LDL-C was associated with an increased risk for hemorrhagic stroke in patients not on antithrombotic therapy. Accumulating evidence showed that low LDL-C was associated with an enhanced bleeding risk in patients on dual antiplatelet therapy following percutaneous coronary intervention. Additionally, low LDL-C was associated with a higher risk for incident atrial fibrillation and thereby, a possible increase in the risk for intracranial hemorrhage after initiation of anticoagulation therapy. The mechanism of low-LDL-C-related bleeding risk has not been fully elucidated. This review summarizes recent evidence of low-LDL-C-related bleeding risk in patients on antithrombotic therapy and discusses potential measures for reducing this risk, underscoring the importance of carefully weighing the pros and cons of aggressive LDL-C lowering in patients on antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: